• A randomized, double-blind, placebo-controlled, parallel-group design conducted at Tokyo, Japan, between May and December 2022 used probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 to test for metabolic parameters in Prediabetics.

• Its mechanism of action is considered to be anti-inflammatory with high interleukin (IL)-10 inducing activity in immune cells by suppressing chronic inflammation in the intestine and visceral adipose tissue and improving insulin resistance, glucose, and lipid metabolism.

• The participants were aged between 20 and 64 years and had prediabetes.

• The participants were instructed to eat the 112-gram test yogurt daily for 12 weeks and continue their regular diet, lifestyle habits, and exercise.

• The current study confirmed that the levels of HbA1c and glycoalbumin decreased significantly in both groups.

• In the OLL2712 group, in comparison with the placebo, the HbA1c returned to baseline levels after intake was stopped.

• The changes in other metabolic parameters, like body weight, tended to increase slightly during the study period, with body mass index increasing significantly.

• The total cholesterol level values did not change.

• Serum IL-6 levels decreased significantly, but serum IL-10 levels increased.

• Also, during the post-observation period (16th and 20th weeks), IL-10 levels decreased significantly in both groups in comparison with those at week 0.

• The study concluded that the ingestion of yogurt containing OLL2712 can prevent glycemic control deterioration and maintain HbA1c levels within the normal range in adults with prediabetes in cases of long-term intake, as its effect declines with time.

Click here to read more.